Integra LifeSciences reports Q3 adjusted EPS 76c, consensus 78c

Reports Q3 revenue $382.4M, consensus $387.12M. “Although the Boston returns weighed further on our third quarter results, we are on track to restart the Boston facility by the end of the year, and we also met two significant CereLink milestones with the relaunch in international markets and submission for regulatory approval in the U.S.,” said Jan De Witte, Integra LifeSciences’ president and CEO. “At the same time, our strong organic growth performance in the Codman Specialty Surgical and Tissue Technologies businesses, excluding Boston, plus advances across our product pipeline, give us confidence in our long-range growth commitments.”